skip to main content

Lung Cancer

Rogel Cancer Center names clinical research young investigators

The awards recognize faculty members’ outstanding clinical research and promising future in oncology.

Expanded lung cancer screening eligibility would save lives

The modeling study looks at the benefits and harms associated with various low-dose computed tomography screening strategies—identifying those that result in the most benefits for a given level of screening.

New inhibitor shows promise against challenging lung, colon cancers

A new inhibitor designed to target what’s been called an “undruggable” genetic mutation showed promising activity against advanced cancers with this mutation.

Screening for lung cancer based on risk could save lives

Changing the way individuals are selected to be screened for lung cancer could prevent 14% of lung cancer deaths per year.

Keytruda given with chemotherapy resulted in 20 percent improved survival for advanced lung cancer patients

In the first large, randomized trial to look at immunotherapy as a first-line cancer treatment, researchers found that adding the immunotherapy drug pembrolizumab to chemotherapy for advanced lung cancer led to better tumor control and overall survival than chemotherapy followed by pembrolizumab.

Pembrolizumab and Chemotherapy Increase Survival for Advanced Lung Cancer Patients

The update on the KEYNOTE-189 trial provides nearly two years data on use of the immunotherapy drug pembrolizumab in combination with platinum-based chemotherapy as a first-line treatment for metastatic non-small cell lung cancer.

Pages